American Shared Hospital Services (NYSE American: AMS) announced today that it will release its first quarter 2026 financial results before the market opens on May 14, 2026, and will hold a conference call to discuss the results at 12:00 pm ET on the same day. The company, a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services, operates through equipment leasing and direct patient care segments.
The conference call will be accessible to domestic callers by dialing 1-844-413-3972 and international callers by dialing 1-412-317-5776 at least 10 minutes prior to the start time. A simultaneous webcast will be available through the company's website at www.ashs.com or directly via this link. A replay of the call will be available from May 14 through May 21, 2026, by dialing 1-855-669-9658 or 1-412-317-0088, access code 6753554. The replay will also be accessible on the company's website.
The announcement underscores the importance of transparency and communication with investors as the company continues to expand its cancer treatment services. American Shared Hospital Services works closely with cancer treatment centers, health systems, and cancer networks in North and South America, providing turnkey solutions to develop and grow cancer service lines. Under health system partnerships, the company shares capital investment costs and profitability based on ownership interests.
Ray Stachowiak, Executive Chairman, and other executives are expected to discuss financial performance, operational highlights, and future growth strategies during the call. The company's first quarter results will provide insights into the demand for its Gamma Knife, proton therapy, and advanced radiation therapy services. As with any forward-looking statements, the company cautions that actual results may differ due to risks such as economic conditions, debt covenant compliance, variability of financial results, changes in CMS reimbursement rates, and integration of acquired businesses.
Investors and analysts are advised to review the company's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2025, for a detailed discussion of risk factors. The earnings call represents a key opportunity for stakeholders to gauge the company's trajectory in the competitive cancer treatment market.
